World leaders in the field of diagnostics will assemble at Dublin City University next week to participate in the launch of the Biomedical Diagnostics Institute by the Taoiseach Bertie Ahern (Irish Prime Minister).
The agenda for the event will include internationally-renowned speakers including Professor Adam Heller, founder of diagnostics giant Therasense. The event will also include a panel discussion entitled “Who Will Monitor Your Health?” on the controversial topic of access to personal health information by third parties such as health insurance companies.
The development of sophisticated diagnostic technologies means that more information will be available to our doctors than ever before. The health benefits offered by these advances are clear, but there are other potential uses for this information that have broader societal implications. For example, could your health insurance policy be linked to your compliance with a healthcare regime, monitored by diagnostic tests? The panel will include Oliver Tattan, CEO and founder of Vivas Health, Gerry McQuaid, Commercial Director of O2 Mobile Communications, and Dr. Karina Halley, Lecturer in Ethics at TCD.
Professor Heller’s talk will focus on the founding of Therasense, a company which developed blood glucose monitoring technology for diabetes management, based on discoveries made in his lab at the University of Texas. TheraSense was acquired in 2004 by Abbott Laboratories for $1.25 billion, the largest acquisition ever in biosensors. TheraSense based sales of Abbott in 2005 exceeded $500 million and the company employs 1,500 people worldwide.
The Biomedical Diagnostics Institute
The Biomedical Diagnostics Institute (BDI) is a unique industrial-clinical-academic research collaboration focused on the development of next generation biomedical diagnostic devices for use in the home or at the Point-of-Care. These advanced devices will enable the detection of life-threatening events long before the critical stage is reached - thus improving people’s lives and enhancing the efficiency of our healthcare system. Research is being carried out to exploit “markers” in blood, breath and saliva that will give these early warnings in illnesses like cancer, heart disease and diabetes, with “exquisite accuracy” according to Professor Brian MacCraith, Director of the Institute.
The integration of fundamental and applied research, from the wide-ranging scientific and engineering disciplines required, into working device demonstrators is a unique feature of the BDI. The BDI brings together key academic researchers, led and hosted by Dublin City University, including the Royal College Surgeons Ireland, National University Ireland Galway and University College Cork; six industrial partners, Åmic, Analog Devices, Becton Dickinson, Enfer Scientific, Hospira, and Inverness Medical Innovations/Unipath, as well as the clinical environment, to form an integrated, cohesive, multi-disciplinary team of more than 70 people.
Shane Kenny | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences